Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Linarić, Petra"'
Autor:
Linarić, Petra, Pavlović Mavić, Mirjana, Mirčevski, Karla, Meštrović, Josipa, Jakšić, Petra, Tečić Vuger, Ana, Vazdar, Ljubica, Šeparović, Robert
Results of our research showed that there was no statistically significant difference in duration of treatment between patients with luminal and non-luminal subtype, same as was reported in CLEOPATRA trial. Analyzing correlation between duration of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::589e85c6a0cd9d7be0fd18de0b51fe36
https://www.bib.irb.hr/1274029
https://www.bib.irb.hr/1274029
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tečić Vuger, Ana, Perić Balja, Melita, Jakšić, Petra, Linarić, Petra, Pavlović Mavić, Mirjana, Vazdar, Ljubica, Šeparović, Robert
Neoadjuvant, i.e. preoperative, systemic antineoplastic treatment (NAT), in patients with breast cancer enables in vivo monitoring of tumor response to applied therapy, tailoring treatment in real –time accordingly, sparing surgical procedures, bet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::de798104747bb8dff63770095b3df808
https://www.bib.irb.hr/1260825
https://www.bib.irb.hr/1260825
Autor:
Pavlović Mavić, Mirjana, Šeparović, Robert, Vazdar, Ljubica, Tečić Vuger, Ana, Jakšić, Petra, Linarić, Petra
Liver is the most common site of metastases from CRC.Surgical resection is the only treatment that offers a chance of long-term survival, however, only a minority of patients is suitable for upfront surgery. In patients with initially unresectable li
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::9b62f547cfa24924392587a5c5aa9e4a
https://doi.org/10.1016/j.annonc.2022.04.287
https://doi.org/10.1016/j.annonc.2022.04.287
Autor:
Linarić, Petra, Mirčevski, Karla, Vazdar, Ljubica, Tečić Vuger, Ana, Jakšić, Petra, Popović, Josipa, Trajbar, Mihaela, Pavlović Mavić, Mirjana, Šeparović, Robert
Osnova liječenja HER2-pozitivnog proširenog raka dojke je kombinacija HER2 blokade i kemoterapije. U metastatskom okruženju, osim učinkovitosti, od primarne su važnosti nuspojave liječenja i kvaliteta života (eng. QoL) bolesnika. U liječenju
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::0ec2905101b36803ad2766a893155837
https://www.bib.irb.hr/1262979
https://www.bib.irb.hr/1262979
Autor:
Vazdar, Ljubica, Linarić, Petra, Pavlović, Mirjana, Tečić Vuger, Ana, Šeparović, Robert, Jurić, Andreja
Abirateron acetate (AA) selectively inhibits the CYP17 enzyme resulting in a decrease in androgen synthesis in the adrenal glands, testicles and prostate tissue. Inhibition of CYP17 reduces serum cortisol levels and increases ACTH secretion through n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::b1833ab60e54e605921b9c2b8fe147ff
https://www.bib.irb.hr/1262955
https://www.bib.irb.hr/1262955
Autor:
Linarić, Petra, Tečić Vuger, Ana, Pavlović Mavič, Mirjana, Vazdar, Ljubica, Jakšić, Petra, Šeparović, Robert
First-line treatment with pertuzumab/trastuzumab/docetaxel significantly improved overall survival for patients with HER2-positive metastatic breast cancer compared with placebo/trastuzumab/docetaxel. Our question is whether there is a statistically
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::76edf61a0a97fbbe949ec23b2483edac
https://www.bib.irb.hr/1264316
https://www.bib.irb.hr/1264316
Autor:
Lepetić, Petra, Linarić, Petra, Jezernik, Dejana, Kanceljak, Kristina, Tečić Vuger, Ana, Pavlović, Mirjana, Vazdar, Ljubica, Šeparović, Robert
Nowadays, immune checkpoint inhibitors (ICI) are a treatment of choice in a wide array of malignancies such as RCC, melanoma, or non - small cell lung carcinoma with significantly improved survival rates. Nivolumab targets programmed death 1 receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::8038b461f54cc4e1c44afa4e317a313d
https://www.bib.irb.hr/1262951
https://www.bib.irb.hr/1262951
Autor:
Pavlović, Mirjana, Šeparović, Robert, Vazdar, Ljubica, Tečić Vuger, Ana, Lepetić, Petra, Linarić, Petra
Body composition has been studied relatively recently as part of oncology trials in different types of tumours in the context of the metabolism of different anticancer drugs, the assessment of response to treat- ment and its toxicity, and consequentl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::345a62ba7a0964e8d54f839fd2e5bfa6
https://www.bib.irb.hr/1139890
https://www.bib.irb.hr/1139890
Autor:
Linarić, Petra, Lepetić, Petra, Jezernik, Dejana, Kanceljak, Kristina, Tečić Vuger, Ana, Pavlović, Mirjana, Vazdar, Ljubica, Šeparović, Robert
Trastuzumab emtansine (TDM-1) in monotherapy is standardised second line treatment option for HER2-positive advanced breast cancer patients, who had previously been treated with trastuzumab and a taxane. The EMILIA study assessed the efficacy and saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::85c6242617d20cb9b7ec29e3910a90cb
https://www.bib.irb.hr/1128321
https://www.bib.irb.hr/1128321